Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing

Core Insights - Predictive Oncology Inc. has entered into a standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global, LP, to secure funding for its drug discovery initiatives [1][2] - The SEPA allows Predictive Oncology to sell up to $10 million worth of its stock at its discretion, with no minimum commitments or penalties for non-use [2] - The company leverages its AI-driven platform, PEDAL, which predicts drug response with 92% accuracy, enhancing drug discovery for cancer treatment [4] Funding Agreement - The SEPA provides Predictive Oncology with a flexible funding source to support ongoing drug discovery, biomarker discovery, and drug repurposing efforts [1] - Yorkville is obligated to purchase the stock, but Predictive Oncology controls the timing and amount of sales [2] - There are no associated warrants, derivatives, or other share classes with the SEPA, and it does not restrict the company's operational activities [2] Company Overview - Predictive Oncology specializes in AI and machine learning applications in drug discovery, aiming to expedite the development of cancer treatments [4] - The company has a biobank of over 150,000 tumor samples, enhancing its drug discovery capabilities [4] - Predictive Oncology is headquartered in Pittsburgh, PA, and offers one of the industry's broadest AI-based drug discovery solutions [4]